We are an experienced team of distinguished innovators, scientists and industry leaders.
John Connolly, PhD
Immune monitoring and immunometabolism
Dr John Connolly is a Research Director for Translational Immunology at the Institute of Molecular and Cellular Biology (IMCB). Additionally, Dr Connolly serves as the Chief Scientific Officer of Parker Institute for Cancer Immunotherapy, a multi-disciplinary centre focused on next-generation therapy in Immuno-oncology. As a human immunologist, his research interests focus on target discovery for immune modulation. An Adjunct Associate Professor of Immunology at Baylor University, he served on the Board of Governors for the Institute of Biomedical Sciences.
Dr Connolly received his Ph.D. in Immunology from Dartmouth Medical School and studied human dendritic cell biology under Dr Michael Fanger. During this time he was involved in the development of immunotherapeutic preclinical models and clinical trials for Glioblastoma multiforme (GBM). He moved to the Baylor Institute for Immunology Research, a fully translational research institute dedicated to rationally designed vaccines against cancer and infectious disease. Dr Connolly served as the Director of Research Initiatives for the Baylor Research Institute, leading a large integrated translational research resource and multi-institutional programs that involved a number of international sites. During his tenure at Baylor, Dr Connolly was a central core facility director of the NIAID Centers for Translational Research on Human Immunology and Biodefense, an NIH funded consortium of basic, translational research and clinical trials focused on vaccine design. Dr Connolly is the past President of the Board of Directors of The American Cancer Society in N. Texas and founding Director of the Singapore Immunology Network’s Immunomonitoring Platform.
Cheng-I Wang, PhD
Dr. Cheng-I Wang is a senior principal investigator at the Singapore Immunology Network (SIgN), A*STAR. He is also an Adjunct Associate Professor at the Nanyang Technological University, Singapore. Dr. Wang’s research focuses on engineering novel functions in antibodies and proteins for the treatment of cancer, infectious and autoimmune diseases.
Anna-Marie Fairhurst, PhD
Systemic immunity, autoimmunity, analytical immunological methods
Dr Anna-Marie Fairhurst, PhD is a Principal Investigator at the Institute of Molecular Biology (IMCB) at ASTAR. She is also Director of the Flow Cytometry Facility at IMCB, and holds an adjunct position as Assist. Professor at the National University of Singapore (NUS).
Dr Fairhurst has over 20 years of experience in Immunology and Rheumatology.
The overall goal of her research is to understand the mechanisms that maintain an effective balance in the immune system for efficient protection from infections, cancer and autoimmunity. She has expertise in advanced Flow Cytometry, Systemic Immunity, Autoimmunity, Lupus, and Inflammation.
Guy Heathers, PhD
Chief Business Officer
After completing his PhD and post-doctoral studies, Guy started his career as a Research Investigator at Hoffmann La Roches’ drug discovery division in Nutley NJ. After almost 7 years with Roche, including completing his MBA studies, Guy returned to London to work in the technology transfer and commercialisation field for a major UK cancer charity, Cancer Research UK. Managing and completing a number of major collaboration and licensing deals, including a number of spin out biotech companies Guy developed his business development career initially in the UK then throughout Europe and finally Asia as he helped created and led a number of companies in Singapore and Australia including Biotech Research Ventures, pSiOncology, Gateway Capital, Amaranth Medical and Cancer Therapeutics. More recently, Guy has worked closely with a number of academic research institutes in Singapore to create successful biotech companies such as Enleofen Bio and Tessa Therapeutics. Today he is a full time member of Hummingbird Bioscience while still advising a number of Singapore biotechs in their IP and business development strategies.